FOXO1 expression is significantly reduced in BPH groups compared to controls, however the treatment with HCQ, FIN or their combination increases its expression, with the combination showing the highest effect (Fig. 3A). The gene discussed is FOXO1; the disease is benign prostatic hyperplasia.